| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20a2c265aefc95a4d1abd1b8f9f25196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c1350787077cf333e1edfd610fa6ff0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de9d74bdf2b414f6c63280fec0d59455 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-37 |
| filingDate |
2012-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c19e0d9c03ca8a21f7af3ac608f91a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5438fa41d2a8692261070c83f242c4a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40393f19a5c9f32c8a66fd4803926d47 |
| publicationDate |
2012-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012316149-A1 |
| titleOfInvention |
Heterocyclic sulfonamide derivatives |
| abstract |
The present invention relates to compounds: n n n n n n n n n n and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases like cancer and inflammation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017033113-A1 |
| priorityDate |
2011-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |